News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,648 Results
Type
Article (43185)
Company Profile (276)
Press Release (694170)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (207003)
Career Advice (2060)
Deals (35977)
Drug Delivery (128)
Drug Development (81874)
Employer Resources (173)
FDA (16622)
Job Trends (15168)
News (350240)
Policy (33211)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2676)
Academic (1)
Accelerated approval (45)
Adcomms (26)
Allergies (169)
Alliances (50394)
ALS (200)
Alzheimer's disease (1783)
Antibody-drug conjugate (ADC) (427)
Approvals (16978)
Artificial intelligence (637)
Autoimmune disease (254)
Automation (53)
Bankruptcy (366)
Best Places to Work (11706)
BIOSECURE Act (20)
Biosimilars (217)
Biotechnology (178)
Bladder cancer (184)
Brain cancer (69)
Breast cancer (722)
Cancer (5670)
Cardiovascular disease (461)
Career advice (1750)
Career pathing (42)
CAR-T (316)
CDC (55)
Celiac Disease (3)
Cell therapy (846)
Cervical cancer (47)
Clinical research (70753)
Collaboration (2028)
Company closure (5)
Compensation (1330)
Complete response letters (77)
COVID-19 (2784)
CRISPR (104)
C-suite (1074)
Cystic fibrosis (150)
Data (7532)
Decentralized trials (3)
Denatured (28)
Depression (158)
Dermatology (74)
Diabetes (571)
Diagnostics (7079)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (312)
Drug pricing (199)
Drug shortages (31)
Duchenne muscular dystrophy (274)
Earnings (91852)
Editorial (64)
Employer branding (21)
Employer resources (152)
Events (119828)
Executive appointments (1067)
FDA (20231)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (34)
Funding (1691)
Gene editing (227)
Generative AI (54)
Gene therapy (684)
GLP-1 (1049)
Government (4766)
Grass and pollen (6)
Guidances (403)
Healthcare (19103)
HIV (79)
Huntington's disease (54)
IgA nephropathy (93)
Immunology and inflammation (281)
Immuno-oncology (86)
Indications (175)
Infectious disease (3122)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (284)
Interviews (322)
IPO (16826)
IRA (50)
Job creations (3768)
Job search strategy (1457)
JPM (59)
Kidney cancer (18)
Labor market (96)
Layoffs (562)
Leadership (38)
Legal (8072)
Liver cancer (99)
Longevity (32)
Lung cancer (756)
Lymphoma (421)
Machine learning (58)
Management (59)
Manufacturing (991)
MASH (180)
Medical device (13967)
Medtech (14061)
Mergers & acquisitions (20373)
Metabolic disorders (1458)
mRNA (196)
Multiple sclerosis (182)
NASH (18)
Neurodegenerative disease (400)
Neuropsychiatric disorders (102)
Neuroscience (3248)
Neurotech (1)
NextGen: Class of 2026 (6561)
Non-profit (4585)
Now hiring (76)
Obesity (682)
Opinion (288)
Ovarian cancer (207)
Pain (245)
Pancreatic cancer (289)
Parkinson's disease (353)
Partnered (34)
Patents (577)
Patient recruitment (636)
Peanut (62)
People (60105)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22069)
Phase 2 (31142)
Phase 3 (23190)
Pipeline (7889)
Policy (308)
Postmarket research (2588)
Preclinical (9482)
Press Release (67)
Prostate cancer (288)
Psychedelics (52)
Radiopharmaceuticals (319)
Rare diseases (1031)
Real estate (6178)
Recruiting (70)
Regulatory (25559)
Reports (55)
Research institute (2473)
Resumes & cover letters (354)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (175)
Series A (282)
Series B (207)
Service/supplier (11)
Sickle cell disease (109)
Special edition (22)
Spinal muscular atrophy (166)
Sponsored (50)
Startups (3680)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (61)
Vaccines (1082)
Venture capital (104)
Weight loss (441)
Women's health (120)
Worklife (20)
Date
Today (185)
Last 7 days (703)
Last 30 days (2803)
Last 365 days (30304)
2026 (10457)
2025 (30320)
2024 (35416)
2023 (40334)
2022 (51425)
2021 (56020)
2020 (54499)
2019 (46972)
2018 (35337)
2017 (32518)
2016 (31990)
2015 (38040)
2014 (31915)
2013 (27002)
2012 (29127)
2011 (29785)
2010 (27830)
Location
Africa (757)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (40442)
Australia (6633)
California (12816)
Canada (3668)
China (1303)
Colorado (549)
Connecticut (553)
Delaware (390)
Europe (87685)
Florida (1918)
Georgia (411)
Hawaii (3)
Idaho (62)
Illinois (1025)
India (88)
Indiana (585)
Iowa (23)
Japan (514)
Kansas (130)
Kentucky (51)
Louisiana (39)
Maine (75)
Maryland (1544)
Massachusetts (9123)
Michigan (354)
Minnesota (700)
Mississippi (6)
Missouri (153)
Montana (36)
Nebraska (29)
Nevada (140)
New Hampshire (85)
New Jersey (3396)
New Mexico (29)
New York (3370)
North Carolina (1639)
North Dakota (8)
Northern California (6377)
Ohio (389)
Oklahoma (23)
Oregon (42)
Pennsylvania (2580)
Puerto Rico (28)
Rhode Island (50)
South America (1143)
South Carolina (85)
South Dakota (2)
Southern California (5053)
Tennessee (206)
Texas (2027)
United States (45334)
Utah (383)
Vermont (1)
Virginia (307)
Washington D.C. (80)
Washington State (1030)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
737,648 Results for "underwriters laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 17, 2026
·
2 min read
Press Releases
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
March 27, 2026
·
3 min read
Press Releases
Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares
March 10, 2026
·
5 min read
Press Releases
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 24, 2026
·
3 min read
Press Releases
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 13, 2026
·
5 min read
Press Releases
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 20, 2026
·
6 min read
Press Releases
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 13, 2026
·
3 min read
Press Releases
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 21, 2026
·
2 min read
Press Releases
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 22, 2026
·
8 min read
Press Releases
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
April 21, 2026
·
3 min read
1 of 73,765
Next
